Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

The last two decades have seen a surge in antimalarial drug development with product
development partnerships taking a leading role. Resistance of Plasmodium falciparum to the …

Malaria remains a major cause of morbidity and mortality in the tropics, with Plasmodium
falciparum responsible for the majority of the disease burden and P. vivax being the …

Background The World Health Organization recommends uncomplicated P. falciparum
malaria is treated using Artemisinin‐based Combination Therapy (ACT). This review aims to …

Malaria remains one of the leading health problems of the developing world, and Uganda
bears a particularly large burden from the disease. Our understanding is limited by a lack of …

The emergence of resistance to artemisinin derivatives in Southeast Asia, manifested as
delayed clearance of Plasmodium falciparum following treatment with artemisinins, is a …

Background Gametocytes are responsible for transmission of malaria from human to
mosquito. Artemisinin combination therapy (ACT) reduces post-treatment gametocyte …

Background Artemisinin combination therapies (ACTs) are currently the preferred option for
treating uncomplicated malaria. Dihydroartemisinin-piperaquine (DHA-PQP) is a promising …

We have analyzed the in vitro chemosensitivity profiles of 115 Kenyan isolates for
chloroquine (CQ), piperaquine, lumefantrine (LM), and dihydroartemisinin in association …

Background. Artemisinin-based combination therapy (ACT) reduces the potential for malaria
transmission, compared with non-ACTs. It is unclear whether this effect differs between …